

1 **Identifying the *C. elegans* vulval transcriptome**

2

3 Qi Zhang^{1,&}

4 Email: qi.zhang@uth.tmc.edu

5

6 Heather Hrach^{2,3}

7 Email: hgeissel@email.asu.edu

8

9 Marco Mangone^{2,3}

10 Email: mangone@asu.edu

11

12 David J. Reiner¹

13 Email: dreiner@tamu.edu

14

15 ¹⁾ Institute of Biosciences and Technology, Department of Translational Medical

16 Science, Texas A&M Health Science Center, Texas A&M University, 2121 W.

17 Holcombe Blvd Houston, TX 77030

18 ²⁾ Molecular and Cellular Biology Graduate Program, Arizona State University, Tempe,

19 AZ;

20 ³⁾ Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute at

21 Arizona State University 1001 S McAllister Ave, Tempe, AZ;

22 & Current address: McGovern Medical School, The University of Texas Health Science
23 Center at Houston, Department of Integrative Biology and Pharmacology, 6431 Fannin
24 St, Houston, TX 77030

25

26 **Running Title:** *lin-31* transcriptome in *C. elegans*

27 **Keywords:** vulval transcriptome, *C. elegans*, *lin-31*, *lag-1*, *mb1-1*, *toe-1*, *shc-1*, *F27A3.4*

28

29

30

31 **ABSTRACT**

32 Development of the *C. elegans* vulva is a classic model of organogenesis. This system, which
33 starts with six equipotent cells, encompasses diverse types of developmental event, including
34 developmental competence, multiple signaling events to control precise and faithful patterning of
35 three cell fates, execution and proliferation of specific cell lineages, and a series of sophisticated
36 morphogenetic events. Early events have been subjected to extensive mutational and genetic
37 investigations and later events to cell biological analyses. We infer the existence of dramatically
38 changing profiles of gene expression that accompanies the observed changes in development.
39 Yet except from serendipitous discovery of several transcription factors expressed in dynamic
40 patterns in vulval lineages, our knowledge of the transcriptomic landscape during vulval
41 development is minimal. This study describes the composition of a vulva-specific transcriptome.
42 We used tissue specific harvesting of mRNAs via immunoprecipitation of epitope-tagged poly(A)
43 binding protein, PAB-1, heterologously expressed by a promoter known to express GFP in vulval
44 cells throughout their development. The identified transcriptome was small but tightly
45 interconnected. From this data set we identified several genes with identified functions in
46 development of the vulva and validated more with promoter-GFP reporters of expression. For one

47 target, *lag-1*, promoter-GFP expression was limited but fluorescent tag of the endogenous protein
48 revealed extensive expression. Thus, we have identified a transcriptome of the *C. elegans* as a
49 launching pad for exploration of functions of these genes in organogenesis.

50

51 INTRODUCTION

52 Organogenesis involves an elaborate series of developmental events that encompass much
53 of the spectrum of developmental biology. This process is presumed to be accompanied by
54 multiple incidences of dynamic spatiotemporal changes in gene expression. Because of
55 sequential developmental decisions, the mechanisms of many later steps can be masked by
56 experimental perturbation of earlier steps, making developmental genetic analysis of the entirety
57 challenging to analyze.

58 The *C. elegans* vulva is a classic system for the genetic investigation of organogenesis
59 (Sternberg, 2005). Thus far, most analysis has focused on the initial patterning of the six vulval
60 precursor cells (VPCs). These roughly equipotent cells are located in an anterior-to-posterior line
61 along the ventral midline of the animal (**Fig. 1A**). Vulval fates are induced in VPCs by an EGF-
62 like signal emanating from the anchor cell (AC), in the nearby ventral gonad, to form a pattern of
63 3°-3°-2°-1°-2°-3° cell fates, with EGFR and Notch receptors functioning centrally in the
64 developmental process (Shin and Reiner 2018). Each cell type undergoes a stereotyped series
65 of cell divisions and subsequent lineal cell behaviors. Understanding of mechanisms of VPC fate
66 specification mostly ends at the level of transcription factors downstream of these EGFR and
67 Notch signals. An exception to this trend is the chance identification of genes whose expression
68 occurs in various sublineages of the vulva and defined a gene regulatory network of transcription
69 factors (Inoue et al. 2002; Kirouac and Sternberg 2003; Inoue et al. 2005; Ririe et al. 2008).
70 Despite the extensive study of initial cell fate patterning in the vulva, a mechanistic understanding
71 of development after this point, including proliferation and morphogenesis, remains to be
72 characterized. (Sternberg 2005).

73 Our group has refined a method to isolate and sequence tissue-specific transcriptomes at
74 high-resolution (Blazie et al. 2015; Blazie et al. 2017). This method, which we named PAT-Seq,
75 takes advantage of the ability of the *C. elegans* ortholog of poly(A)-binding protein, PAB-1, to bind
76 poly(A) tails of mature mRNAs. In this method, heterologously expressed PAB-1 protein is tagged
77 with a 3xFLAG epitope and fused to the green fluorescence protein, GFP, for visualization
78 purposes. The construct is then expressed in selected *C. elegans* tissues using defined tissue-
79 specific promoters. Transgenic animals are then recovered, their lysate is subjected to
80 immunoprecipitation with an anti-FLAG antibody, and the attached mRNAs are sequenced. This
81 method is reliable and produces consistent results with minimal background noise, even using
82 small tissues (Blazie et al. 2017).

83 Here we applied the PAT-Seq method to isolate, sequence, and define the transcriptome of
84 the *C. elegans* vulva throughout development. Overall, the vulva transcriptome is smaller than
85 other tissues but highly interconnected. Selected identified genes were further analyzed by
86 generating extrachromosomal transgenes containing transcriptional GFP fusions as reporters for
87 promoter expression; some of these reporters were expressed in VPCs and all in other tissues.
88 A GFP reporter for one gene, *lag-1*, revealed expression in VPCs as expected from prior
89 mechanistic studies. Still, the expression in the animal was far more limited than expected based
90 on mutant phenotypes. We used CRISPR to tag the endogenous *lag-1* gene. We observed
91 widespread and dynamic expression of LAG-1 protein, including in VPCs. Our analysis uncovers
92 a large set of genes expressed in VPCs and provides a stepping-off point for further exploration
93 of the genetic basis of organogenesis.

94

95 **RESULTS**

96

97 **Engineering the vulval cell lineage for transcriptomic sampling**

98 Identifying a tissue-specific transcriptome requires expressing a bait protein specifically in the
99 tissue of interest. The *lin-31* gene encodes the *C. elegans* ortholog of FoxB transcription factors.
100 LIN-31 is a terminal selector protein that functions in collaboration with LIN-1/Ets and the Mediator
101 Complex to mediate induction of vulval fates (Miller et al. 1993; Beitel et al. 1995; Miller et al.
102 1996; Tan et al. 1998; Hart et al. 2000; Grants et al. 2016; Underwood et al. 2017). Yet, unlike
103 LIN-1, genetic perturbation of LIN-31 is described as impacting only the VPCs (Miller et al. 1993;
104 Tan et al. 1998; Miller et al. 2000). Furthermore, the promoter of *lin-31* drives GFP expression
105 chiefly in the VPCs (Tan et al. 1998). Thus, we used the *lin-31* promoter to transgenically express
106 bait protein in the VPCs throughout development.

107 The *C. elegans* ortholog of polyadenylation binding protein 1, PAB-1, specifically binds poly(A)
108 tails of mature mRNAs and can be used to immunoprecipitate mRNAs from whole-RNA
109 preparations (Blazie et al. 2015; Blazie et al. 2017). Tissue-specific expression of PAB-1 with GFP
110 and an epitope tag has been used to identify tissue-specific transcriptomes from large tissues like
111 neurons, intestine, hypodermis, and muscle, as well as smaller subsets of specific neuron types
112 (Blazie et al. 2017).

113 We cloned a sequence encoding a fusion of GFP, PAB-1, and 3xFLAG epitope into a vector
114 containing the *lin-31* promoter (**Fig. 1B**). We generated transgenic extrachromosomal arrays,
115 randomly integrated arrays into the genome to generate *rels27* and *rels28*, both consisting of $P_{lin-31}::GFP::PAB-1::3xFLAG + P_{myo-2}::GFP$ (i.e. "+PAB-1"), and outcrossed to the wild type N2 strain
116 to generate DV3507 and DV3509, respectively. We similarly generated *rels30*, expressing $P_{lin-31}::GFP::3xFLAG + P_{myo-2}::GFP$ (i.e. "-PAB-1") and outcrossed to the wild type to generate
117 DV3520. Critically, *rels30* expresses control protein lacking the PAB-1 sequences.

120 Analysis of *rels28*($P_{lin-31}::GFP::PAB-1::3xFLAG + P_{myo-2}::GFP$)-bearing animals using DIC and
121 epifluorescence microscopy revealed expression of GFP in vulval lineages throughout larval
122 development, from the first (L1) to the fourth (L4) larval stages and young adult (YA) (**Fig. 1C**).
123 *rels27* and *rels30* similarly expressed GFP in vulval lineages post-embryonically. We also

124 observed additional expression in a small number of unidentified cells in the head and tail. The
125 resulting “+PAB-1” bait- and “-PAB-1” control-expressing transgenes would subsequently be used
126 for identification of the transcriptome of the vulval lineages. However, we note that additional
127 expression in other cells would identify a transcriptome of mixed lineages (see Discussion). We
128 anticipate that subsequent validation of putative VPC-specific genes via promoter::gfp fusion
129 analysis should determine which are expressed in the vulval lineages.

130

131 **Identifying the transcriptome of the vulval lineage**

132 We have prepared two independent transgenic strains expressing our vulva-specific pulldown
133 construct (“+PAB-1” biological replicates; DV3507 and DV3509) and one control strain in which
134 we deleted sequences encoding PAB-1 (DV3520; “-PAB-1” negative control). We performed each
135 immunoprecipitation in duplicate (technical replicates), processing a total of six samples. We
136 obtained approximately ~90M mappable reads for each biological and technical replicate and
137 ~30M mappable reads for our negative control strain DV3520. We could map more than 90% of
138 the total reads across all samples (**Supplemental Figure S1A**). The results obtained with our
139 biological replicates correlate well (**Supplemental Figure S1B-C**).

140

141 **The *C. elegans* vulva transcriptome**

142 Using our PAT-Seq approach, we were able to map 1,671 protein-coding genes in the *C. elegans*
143 vulva, which corresponds to 8.2% of all *C. elegans* protein-coding genes (20,362 protein-coding
144 genes; WS250; **Fig. 2A and Supplemental Table S1**). As expected, a GO term analysis
145 highlights ‘intracellular anatomical structure’, ‘MAP kinase pathway’, ‘developmental processes,’
146 which are all entries consistent with the tissue of origin of our immunoprecipitated RNAs (**Fig.**
147 **2B**). While several of our top hits are genes with unknown functions, (e.g., *F27D4.4*, *Y65A5A*,
148 *fipr-1*, and *F49B2.3*), many others have been previously linked to vulval development or
149 morphogenesis. For example, the *C. elegans* ortholog of translation elongation factor 2 *EEF-2*

150 (Fraser et al. 2000), a GTP-binding protein required for embryogenesis and vulval
151 morphogenesis, expressed during all stages of development; the coiled-coil domain protein GEI-
152 4, is required for embryonic viability, fertility, and vulval morphogenesis (Poulin et al. 2005); and
153 the *C. elegans* ortholog of *Drosophila* NURF301, NURF-1, a member of the NURF chromatin
154 remodeling complex, which is also known to regulate vulval development (Andersen et al. 2006)
155 (**Fig. 2 and Supplemental Table S1**). We also detected several known transcription factors,
156 including *lin-22*, *lin-31*, *eor-1*, *lag-1*, and *pop-1*, all known to be expressed and functioning in vulval
157 lineages (**Fig. 2 and Supplemental Table S1**).

158 In addition to the well-known vulval marker *lin-31*, other genes mutated to a lineage-defective
159 phenotypes during development of the vulva were identified by our sequencing effort, including
160 *lin-22*, *lin-24*, *lin-41*, and *lin-42*. *lin-22* encodes an ortholog of human HES1 and HES6 (hes family
161 bHLH transcription factors 1 and 6; Schlager et al. 2006). *lin-24* was originally identified in a
162 screen for mutations that result in altered vulval cell lineages and is expressed in vulval lineages
163 (Ferguson et al. 1987; Galvin et al. 2008). *lin-41* and *lin-42* are genes involved in the heterochronic
164 pathway to regulate developmental switches that occur in multiple tissues, including the vulva
165 (Tennessen et al. 2006; Parry et al. 2007; **Fig. 2 and Supplemental Table S1**).

166 We also identified 23 genes that, when mutated, confer defective locomotion (Uncoordinated;
167 “Unc”). Some of these, like UNC-31, an ortholog of the human CADPS (calcium-dependent
168 secretion activator) required for the Ca²⁺-regulated exocytosis of secretory vesicles, would be
169 presumed to be abundant contaminating transcripts associated with the neurons in which our
170 “+PAB-1” bait protein is also expressed (not shown). And yet UNC-31 is expressed in certain
171 vulval sublineages (Speese et al. 2007). UNC-32 is a vacuolar proton-transporting ATPase (V-
172 ATPase), expressed in the vulva in adults, that contributes to a protruding vulva phenotype when
173 depleted (Oka et al. 2001; Pujol et al. 2001; Shephard et al. 2011).

174 Other “Unc” genes are more conventionally associated with the development of the vulva.
175 UNC-73 is an ortholog of mammalian TRIO (Steven et al. 1998), a guanyl-nucleotide exchange

176 factor (GEF) that stimulates GTP-loading on Rho family small GTPases like CED-10/Rac and
177 MIG-2/RhoG, which control cytoskeletal dynamics. UNC-73, CED-10, and MIG-2 regulate vulval
178 morphogenesis and extensive axonal growth cone and cell migration events (Steven et al. 1998;
179 Kishore and Sundaram 2002). UNC-62 is the ortholog of *Drosophila Homothorax* (mammalian
180 Meis/Prep), a transcription factor that regulates the development of many tissues, including vulval
181 lineages (Yang et al. 2005).

182 Other previously identified genes with functions in the vulva are SQV-6, which is similar to
183 the human protein xylosyltransferase involved in modification of proteoglycan cores, localizes in
184 the Golgi and endoplasmic reticulum membranes, and is required for vulval morphogenesis
185 (Hwang et al. 2003), and HMP-2, a β -Catenin required for epithelial cell migration and elongation
186 during embryo morphogenesis and necessary for vulva morphogenesis (Costa et al. 1998; Hoier
187 et al. 2000; **Fig. 2 and Supplemental Table S1**). (A novel feature of *C. elegans* is that
188 transcriptional and cytoskeletal functions of β -catenin are performed by distinct paralogs, BAR-1
189 and HMP-2, respectively, rather than the same protein as in other systems (Eisenmann 2005)).

190 The gene network shaped by our identified genes, although small, is highly interconnected
191 (**Fig. 2C**).

192

193 **miRNA targets**

194 MicroRNAs have been found to be involved in the morphogenesis of the vulva. *let-7* is expressed
195 in the vulval tissue and found to target the 3'UTRs of several genes, including the 3'UTR of the
196 *lin-41* heterochronic gene, to prevent vulval rupturing (Ecsedi et al. 2015), and in the 3'UTR of *let-*
197 *60*, which encodes the Ras ortholog, and the genes for mammalian Ras orthologs (Grosshans et
198 al. 2005). We sought to identify potential miRNAs and their targets expressed in the vulva. We
199 parsed our dataset using the MIRANDA software (Enright et al. 2003) and identified 1,128
200 predicted targets for 114 mature *C. elegans* miRNAs (**Fig. 2C and Supplemental Table S2**). The

201 most abundant miRNA targets in our study are those of miR-247, potentially targeting 157 vulval-
202 expressed genes, followed by those of miR-85 (85 genes) and miR-255 (56 genes). Sequences
203 upstream of the initiating ATG for *mir-241* drive a GFP reporter in the vulva (Martinez et al. 2008).
204 Unfortunately, our PAT-Seq method was not designed to identify miRNAs, and more experiments
205 need to be performed to validate the presence of these miRNAs in this tissue.

206

207 **Promoter Analysis**

208 Next, we aimed to study the promoter composition of the genes detected in our study with the
209 goal of identifying novel *cis*-acting elements potentially used by vulva-specific transcription
210 factors. We have extracted DNA regions 500 bp upstream and 100 nt downstream from the
211 transcription start of our top 100 genes detected in our study (**Supplemental Fig. S2**). We
212 identified three motifs. The first motif, CAACCTGC, is recognized by the human transcription
213 factor TCF12, a basic helix-loop-helix (bHLH) factor that in humans regulates lineage-specific
214 gene expression through the formation of heterodimers with other bHLH E-proteins using mainly
215 the ERK and WNT signaling pathway (Belle and Zhuang 2014); **Supplemental Fig. S2B Top**
216 **Panel**). The second motif, CAATTAA, in humans is targeted by Hmx2, a Homeodomain
217 transcription factor and plays an important role in organ morphogenesis and development during
218 embryogenesis (Wang and Lufkin 2005) pathway (**Supplemental Fig. S2B Middle Panel**). The
219 third motif, CCACGCCAC, in humans is targeted by SP3, a three-zinc finger Kruppel-related
220 transcription factor that stimulates or represses the transcription of numerous genes
221 (**Supplemental Fig. S2B Middle Panel**). Unfortunately, each of these factors is part of large
222 families and does not have reported worm orthologs, so more experiments need to be performed
223 to rule out their function in the context of *C. elegans* transcriptome characterization.

224

225 **Validating selected candidate genes hypothesized to be expressed in VPC lineages**

226 Our PAT-Seq analysis, based on a comparison of data sets generated with $P_{lin-31}::GFP::PAB-$
227 $1::3xFLAG$ “+PAB-1” vs. $P_{lin-31}::GFP::3xFLAG$ “-PAB-1” control, generated a set of genes
228 potentially expressed in VPCs. Notably, the expression of this set of genes is not expected to be
229 exclusive to VPCs and may also be expressed in other tissues.

230 To validate our approach, we selected candidate genes identified in this study for analysis
231 with promoter::GFP transgenes to ascertain whether they are expressed in VPCs. We cloned
232 sequences upstream of the ATG initiator methionine codon for several genes into vector
233 pPDPD95.67 with 2xNLS::GFP (nuclear localization signal) and generated extrachromosomal
234 arrays harboring these clones (**Fig. 3A**). Given the interests of our research program, we focused
235 on genes potentially regulating signaling and/or developmental biology, with some randomly
236 selected genes included.

237 The *lag-1* gene encodes the *C. elegans* ortholog of *Drosophila* Suppressor of Hairless/Su(H),
238 the central nuclear transcriptional regulator downstream of the Notch receptor. Because of the
239 role of LIN-12/Notch in the induction of 2° VPC fate, expression of LAG-1 is expected in VPCs.
240 Indeed, we observed GFP expression driven by *lag-1a* promoter sequences in VPCs (**Fig. 3B**
241 **Panel i**). However, despite the broad use of LIN-12/Notch and GLP-1/Notch in development
242 (Priess 2005; Greenwald and Kovall 2013), we did not observe expression from the *lag-1a*
243 promoter in other tissues, including the germline and embryo. This observation reinforces the
244 notion that sequences defined as “promoters” are limited by an arbitrary distance upstream of
245 initiator methionine codons. Key regulatory sequences are likely to be present further upstream,
246 in coding sequences, or downstream of codon sequences (*e.g.* a repressive element for the *egl-*
247 *1* gene located 5.6 kb downstream of the termination codon of *egl-1*; (Conradt and Horvitz 1999).

248 Sequences upstream of *toe-1* (Target Of ERK kinase MPK-1) (Arur et al. 2009), a putative
249 nucleolar protein also identified in this study drove expression of GFP strongly in nuclei of many
250 cells, including VPCs (**Fig. 3B Panel ii**).

251 *mb1-1*, which encodes an RNA-binding protein from two promoters, *a* and *b*, showed diverse
252 expression from the two promoters. Sequences upstream of *mb1-1a* drove expression in a subset
253 of neurons while those upstream of *mb1-1b* drove expression in the vicinity of the ventral nerve
254 cord but not in VPCs (**Fig. 3B Panel iii and iv**). Sequences upstream of the *a* isoform of *shc-1*, a
255 signaling adaptor protein (SHC (Src Homology domain C-terminal) adaptor ortholog), drove
256 expression in the pharynx, intestine, and neurons but not VPCs (**Fig. 3B Panel v**). Finally, we
257 tested the promoter of a not yet characterized gene, *F23A7.4*, which encodes a *C. elegans*-
258 specific protein. Although in our dataset, we were unable to detect its expression in VPCs but
259 detected its expression in unidentified neurons (**Fig. 3B Panel vi**).

260

261 **CRISPR tagged *lag-1* gene reveals expression broadly throughout development.**

262 We speculated that the reason why we were unable to detect *lag-1* expression in the germline
263 and embryos – but still detect it in the vulva – was because this gene possesses four splice
264 variants that differ at their 5' end but share the same 3' end (**Fig. 4A**). We hypothesized that
265 perhaps each of these isoforms possess differential tissue localization, and our cloned promoter
266 region, which was specific to the *a* isoform, while driving strong vulva expression, was not enough
267 to drive the expression of other *lag-1* isoforms, perhaps expressed in germline and embryos. To
268 further explore the “missing” expression from our cloned *lag-1a* putative promoter sequence in
269 the germline and embryos, we used CRISPR technology to tag the endogenous *lag-1* gene at the
270 3' end with sequences encoding mNeonGreen (mNG) fluorescent protein and a 3xFLAG epitope.
271 We expected to detect full-length protein fusions regardless of the use of different promoters at
272 the 5' end. Specifically, we used the “self-excising cassette” (SEC) method for two-step positive-
273 negative selection from a single plasmid and injection (Dickinson et al. 2015; **Fig. 4B**). Proper
274 insertion was validated by PCR and western blotting of worm lysates probed with anti-FLAG (for
275 FLAG-tagged LAG-1) and anti- α -tubulin (control). Anti-FLAG antibodies recognized two major

276 tagged protein products (**Fig. 4C**). While this study was in progress, another group described the
277 expression of tagged LAG-1, with similar results (Luo et al. 2020).

278 As expected based on functional studies (Christensen et al. 1996; Yoo et al. 2004; Greenwald
279 2005; Kimble and Crittenden 2005; Priess 2005; Yoo and Greenwald 2005), we observed LAG-
280 1::mNeonGreen expression broadly and localized to nuclei in the vulval lineages and neighboring
281 uterine lineages throughout larval development (**Fig. 5**). We also observed dynamic LAG-1
282 expression in various embryonic cells (**Fig. 6**). LAG-1::mNeonGreen expression was also
283 observed broadly throughout the animal at various stages (**Fig. 7A,B**). In conjunction with the
284 description of other expression patterns derived from endogenous genes tagged by CRISPR from
285 our lab (Rasmussen et al. 2018; Shin et al. 2018; Shin et al. 2019; Duong et al. 2020; Rasmussen
286 and Reiner 2021), we concluded that promoter::GFP fusions are limiting. Positive results are likely
287 informative, but the absence of expression often can be a result of regulatory sequences missing
288 from transcriptional expression reporters.

289

290 **DISCUSSION**

291 The *C. elegans* vulva is an effective model for the study of signaling cues and morphogenic
292 processes required in development to produce an organ. Although numerous studies thus far
293 have highlighted fundamental processes and key genes involved in its morphogenesis, the
294 composition of its transcriptome and its interactome are still not known. Here we have used PAT-
295 Seq, a method that allows the isolation of high-quality tissue-specific transcriptomes, to sequence
296 and study the *C. elegans* vulval transcriptome. We have identified 1,671 high-quality *bona fide*
297 genes expressed in this tissue and developed accurate miRNA targeting predictions in this
298 dataset. The vulva dataset is small but highly interconnected, as expected because of the intricate
299 series of events needed to produce the mature vulva. Within its transcriptome, we defined 39
300 transcription factors, 49 kinases, 50 membrane-associated proteins and 118 genes containing an
301 RNA binding domain (**Supplemental Table S1**). Our promoter analysis in **Supplemental Fig. S2**

302 identified three specific DNA elements enriched in promoters of vulva-transcribed genes, which
303 are targeted by transcription factors previously not associated with vulva development in worms
304 (TCF12, Hmx2, and Sp3).

305 Unfortunately, there are no available *C. elegans* vulva datasets we could use to compare our
306 results, and we cannot conclusively pinpoint all the genes expressed in this organ. Importantly,
307 we have sequenced two independently generated transgenic animal lines (biological replicates
308 DV3507 and DV3509), with a technical replicate each, and subtracted the genes identified in the
309 sequencing results of our negative control (DV3520), which is unable to bind poly(A) tails, to thus
310 isolate transcripts specific to the vulva. Our PCA analysis (**Supplemental Fig. S1**) shows that our
311 two biological replicates correlate well with each other, suggesting little contamination.

312 Using transgenes harboring promoter::GFP transcriptional fusion reporters, we also were able
313 to validate putative targets identified in our study (e.g. *lag-1*, *toe-1*), as being expressed in the
314 VPCs, while for others (e.g. *shc-1*, *mbl-1* and *F23A7.4*) we were unable to detect expression in
315 VPCs, perhaps because of false positive candidates or the insufficiency of the promoter::GFP
316 transgenes in reflecting the full expression patterns of genes. One validated target, *lag-1*,
317 exhibited limited expression via promoter::GFP fusion analysis (**Fig. 3**), but our CRISPR tagging
318 of the endogenous protein revealed spatiotemporally broad and dynamic expression (**Figs. 5-7**).

319 A caveat to our analysis is that the *lin-31* promoter sequences derived from the plasmid pB255
320 (Tan et al. 1998) also drive expression of GFP in two to three small cells, perhaps neurons, each
321 in the head and tail. We have been unable to identify these cells, though could likely do so using
322 a comprehensive label for neurons in the worm (Yemini et al. 2021). But the presence of additional
323 non-vulval cells, albeit of smaller collective volume than the vulval cells, indicates that a subset of
324 our identified genes is likely specific to non-vulval lineages. This set cannot be discriminated at
325 present but likely represents a significant source of false-positive candidates in our transcriptome
326 set. A solution to this conundrum would be to perform deletion analysis on the *lin-31* promoter to

327 identify regulatory DNA sequences specific to these ancillary cells but not vulval lineages. Such
328 analysis would position us to perform PAT-SEQ that is more specific to vulval lineages.

329 Another *caveat* is the fusion of 3° VPC cells to the hyp7 syncytium after initial patterning of
330 VPC cell fates. VPCs are specialized hypodermal cells surrounded by nonspecialized
331 hypodermis, called the hyp7, a syncytium comprised of many fused hypodermal cells. 1° and 2°
332 cells (**Fig. 1A**) go through stereotyped series of cell divisions, but non-vulval 3° cells divide once
333 and fuse to the surrounding syncytium. The release of “+PAB-1” protein into the general hyp7
334 syncytium may result in identification of transcripts specific to the hyp7. But we expect the
335 concentration of “+PAB-1” protein in the hyp7 after fusion of the 3° daughters to be relatively low,
336 and GFP in the hyp7 was not observed after the 3° fusion at the L3 stage. Unlike improvement of
337 the *lin-31* promoter used to express “+PAB-1” protein, we foresee no plan for working around this
338 limitation to our approach.

339 A final limitation to our approach is the complexity of the vulval system over time. Our bait
340 “+PAB-1” protein and control “-PAB-1” protein proteins were expressed from the L1 to young adult
341 stages (**Fig. 1C**), yet we obtained a sample of mixed stage populations. During this time,
342 developmental competence of P3.p-P8.p is established through the actions of multiple
343 transcription factors including Homeobox proteins (Clandinin et al. 1997; Wagmaister et al. 2006a;
344 Wagmaister et al. 2006b; Myers and Greenwald 2007; Takacs-Vellai et al. 2007), unexpectedly
345 early MPK-1/ERK signaling observed in the L2 VPCs prior to conventional induction in the L3 (de
346 la Cova et al. 2017), the VPCs have at least five signals activated (three major and two
347 modulatory; Gleason et al. 2006; Nakdimon et al. 2012; Shin et al. 2019; reviewed in Shin and
348 Reiner 2018)), fusion of 3°s (Shemer and Podbilewicz 2002), three rounds of distinctive and
349 highly reproducible cell divisions specific to 1° and 2° lineages specifically (Sulston and Horvitz
350 1977; Braendle and Felix 2008), polarity of 2° lineages (Inoue et al. 2004; Gleason et al. 2006;
351 Green et al. 2007; Green et al. 2008; Kidd et al. 2015), and a sophisticated series of
352 morphogenetic events ending with joining of the vulva and uterus (Hagedorn and Sherwood 2011;

353 Cohen et al. 2020; Spiri et al. 2022) to form a tube through which eggs are laid and males deposit
354 sperm in the spermatheca. The developmental complexity of this system, probably reflected by
355 the complexity of transcriptional changes, surely must exceed the resolution of our PAT-Seq
356 analysis, probably by a great margin.

357 Yet it is important that we pilot this technology in the vulval system to be able to refine our
358 analysis in the future. A more specific vulva promoter driving bait “+PAB-1” protein and control “-
359 PAB-1” protein proteins coupled with tight synchrony of animal populations may yield coherent
360 temporal “slices” of gene expression in the vulval system over time. Even though such an
361 approach would not be able to distinguish between different vulval lineages, deconvoluting gene
362 expression in this manner may shed important light on the process of organogenesis and identify
363 specific candidates for further analysis later in development. Such PAT-Seq analysis with more
364 refined temporal lysates could also be performed with “+PAB-1” bait protein expressed in specific
365 lineages or sublineages after initially patterning, or in backgrounds where patterning signals are
366 altered mutationally, to identify sets of transcriptional client genes that respond to those signals.

367

368

369 **MATERIALS AND METHODS**

370 ***C. elegans* culturing and handling**

371 Strains were derived from the wild-type Bristol N2 parent strain and grown at 20°C (Brenner
372 1974). Nomenclature conforms to that of the field (Horvitz et al. 1979). Crosses were performed
373 using standard methods and details are available upon request. Names and genotypes of strains
374 used in this study are listed in **Supplemental Table S3**.

375

376 ***Generation of plasmids and CRISPR strains***

377 Plasmids containing sequences encoding GFP::PAB-1::3xFLAG “+PAB-1” bait and
378 GFP::3xFLAG “-PAB-1” control were generated through the following steps. First, we inverse PCR

379 linearized vector pB255 vector (10,873 bp; Tan et al. 1998) with *lin31* promoter and enhancer
380 using the primer pair QZ35f and QZ36r (see **Supplemental Table S3**; the requirement of inverted
381 *lin-31* coding sequences to function as an enhancer were included in the original promoter::GFP
382 reporter for *lin-31*; Tan et al. 1998). Second, the GFP::PAB-1::3xFLAG fragment (3,130bp) was
383 PCR amplified from plasmid p221 using primer pair QZ17f and QZ23r. Third, with overlapping
384 homology arms included in both of these primers, Gibson assembly cloning kit (NEB) was applied
385 to ligate vector and GFP::PAB-1::3xFLAG fragment to generate plasmid pQZ2. Fourth, pQZ2 was
386 amplified by inverse PCR using primers QZ37r and QZ38f to delete the *pab-1* gene sequences
387 to generate plasmid pQZ3. Downstream of all inserts is the *unc-54* 3'UTR contained in many *C.*
388 *elegans* vectors.

389 Plasmids pQZ2 (GFP::PAB-1::3xFLAG) and pQZ3 (GFP::3xFLAG) were injected with the
390 pPD118.33 ($P_{myo-2}::GFP$) co-injection marker in a mix of linearized plasmid and digested genomic
391 DNA designed to mitigate silencing observed with heterologous *lin-31* promoter (A. Fire, personal
392 communication; R.E.W. Kaplan and D. Reiner, unpublished): 1 ng/ μ l SacII-linearized P_{lin-31} -
393 harboring plasmid, 0.25 ng/ μ l pPD118.33 ($P_{myo-2}::gfp$), 50 ng/ μ l EcoRV-digested and column
394 purified *C. elegans* wild-type genomic DNA. Transgenes were tracked through crosses using a
395 Nikon stereofluorescence microscope, based on their green pharynges. Unstable
396 extrachromosomal transgenic lines with moderate levels of pharyngeal GFP were integrated with
397 UV irradiation at the L4 stage using a 2400 UV crosslinker (Stratagene). UV dosage was
398 calibrated by a dosage curve and selecting a dosage just below that which confers sterility. F2
399 progeny of irradiated animals were screened for 100% stable inheritance of green pharynges,
400 resulting in integrated transgenes *rels27*($P_{lin-31}::gfp::pab-1::3xFLAG$), *rels28* ($P_{lin-31}::gfp::pab-$
401 $1::3xFLAG$), resulting in strains DV3507 and DV3509, respectively, and *rels30* (P_{lin-}
402 $31::gfp::3xFLAG$), resulting in strain DV3520. Resulting integrated arrays were outcrossed to the

403 N2 wild type 4x. Expression was confirmed by epifluorescence and no silencing of vulval signal
404 was ever observed.

405 Transcriptional promoter::GFP fusion plasmids were generated by amplifying regulatory
406 sequences upstream of the initiating ATG codon and cloning into plasmid pPD95.67 digested with
407 restriction enzymes HindIII and XmaI. Extrachromosomal arrays harboring GFP reporters were
408 generated by microinjecting N2 wild-type animals with reporter plasmids at 40 ng/ μ l and co-
409 injection marker pCFJ90 ($P_{myo-2}::mCherry$) at 1 ng/ μ l.

410

411 ***Fluorescence microscopy***

412 Some animal handling was performed using a Nikon SMZ18 stereofluorescence microscope with
413 1.0x and 1.6x objectives, hybrid light transmitting base, GFP filter cube and a Xylis LED lamp. For
414 slide-based imaging live animals were mounted in M9 buffer containing 2% tetramisole on slides
415 with a 3% NG agar pad. DIC and epifluorescence images were acquired using a Nikon Eclipse Ni
416 microscope and captured using NIS-Elements AR 4.20.00 software. Confocal images were
417 acquired using DIC optics and fluorescence microscopy using a Nikon A1si confocal microscope
418 with a 488 nm laser. Captured images were processed using NIS Elements Advanced research,
419 version 4.40 (Nikon).

420

421 ***Immunoblotting***

422 Animals were washed from plates and boiled in 4% SDS loading buffer at 95°C for 2 minutes to
423 prepare lysates. Lysates were separated on 4-15% SDS gels (Bio-Rad), transferred to PVDF
424 membrane (EMD Millipore Immobilon), and probed with mouse anti-FLAG antibody (Sigma-
425 Aldrich #F1804) or monoclonal mouse anti- α -tubulin antibody (Sigma-Aldrich #T6199) diluted
426 1:2000 in blocking solution overnight. Following primary incubation, blots were incubated with
427 goat anti-mouse HRP-conjugated secondary antibody (MilliporeSigma 12-349) diluted 1:5000 in

428 blocking solution for 1 hr. Immunoblots were then developed using ECL kit (Thermo Fisher
429 Scientific) and X-ray film (Phenix).

430

431 ***RNA immunoprecipitation***

432 The transgenic *C. elegans* strains used for RNA immunoprecipitations were maintained at
433 20°C on nematode growth media (NGM) agar plates seeded with OP50-1. Animals were then
434 harvested, suspended and crosslinked in 0.5% paraformaldehyde solution for one hour at 4°C as
435 previously described (Blazie et al. 2015; Blazie et al. 2017; Hrach et al. 2020). We used an animal
436 pellet of approximately 1 mL for each immunoprecipitation. Following centrifugation, animals were
437 pelleted at 1,500 rpm, washed twice with M9 buffer, and flash-frozen in an ethanol-dry ice bath.
438 The recovered pellets were thawed on ice and suspended in 2 mL of lysis buffer (150 mM NaCl,
439 25 mM HEPES, pH 7.5, 0.2 mM dithiothreitol (DTT), 30% glycerol, 0.0625% RNAsin, 1% Triton
440 X-100; Blazie et al. 2015). The lysate was subjected to sonication (Fisher Scientific) for five
441 minutes at 4°C (amplitude 20%, 10 sec pulses, 50 sec rest between pulses) and centrifuged at
442 21,000 x g for 15 min at 4°C. 1 ml of supernatant was added per 100 µl of Anti-FLAG® M2
443 Magnetic Beads (Sigma-Aldrich) and incubated overnight at 4°C in a tube rotisserie rotator
444 (Barnstead international). The mRNA immunoprecipitation step was carried out as previously
445 described (Blazie et al. 2015; Blazie et al. 2017; Hrach et al. 2020). At the completion of the
446 immunoprecipitation step, the precipitated RNA was extracted using Direct-zol RNA Miniprep Plus
447 kit (R2070, Zymo Research), suspended in nuclease-free water, and quantified. Each RNA IP
448 was performed in duplicate to produce two technical replicates for each of the following samples:
449 DV3507, DV3509, and DV3520 (total six immunoprecipitations).

450

451 ***cDNA library preparation and sequencing***

452 We prepared 6 mixed-stages cDNA libraries from the following worm strains: DV3507,
453 DV3509, and DV3520. Each cDNA library was prepared using 100 ng of precipitated mRNAs. We
454 used the SPIA (Single Primer Isothermal Amplification) technology to prepare each cDNA library
455 (IntegenX and NuGEN, San Carlos, CA) as previously described (Blazie et al. 2015; Blazie et al.
456 2017). Briefly, the cDNA was sheared using a Covaris S220 system (Covaris, Woburn, MA), and
457 the resultant fragments were sequenced using the HiSeq platform (Illumina, San Diego, CA). We
458 obtained between 70M to 12M of mappable reads across all six datasets.

459

460 ***Bioinformatics analysis***

461 Raw Reads Mapping: The FASTQ files corresponding to the two datasets and the control with
462 each corresponding replicate (total 6 datasets), were mapped to the *C. elegans* gene model
463 WS250 using the Bowtie 2 algorithm (Langmead and Salzberg 2012) with the following
464 parameters: --local -D 20 -R 3 -L 11 -N 1 -p 40 --gbar 1 -mp 3. The mapped reads were then
465 converted into a bam format and sorted using SAMtools software using standard parameters (Li
466 et al. 2009). We processed ~500M reads obtained from all our datasets combined and obtained
467 a median mapping success of ~90%.

468 Cufflinks/Cuffdiff Analysis: Expression levels of genes obtained in each dataset were estimated
469 from the bam files using the Cufflinks software (Trapnell et al. 2010). We calculated the fragment
470 per kilobase per million bases (FPKM) number in each experiment and performed each
471 comparison using the Cuffdiff algorithm (Trapnell et al. 2010). We used the median FPKM value
472 ≥ 1 in each dataset as a threshold to define positive gene expression levels. The results are
473 shown in **Supplemental Fig. S1 and Supplemental Table S2** using scores obtained by the
474 Cuffdiff algorithm (Trapnell et al. 2010) and plotted using the CummeRbund package.

475

476 ***Network Analysis***

477 The network shown in Main Figure 2C was constructed parsing the 1,671 hits identified in this
478 study using the STRING algorithm (v. 11.5) (Szklarczyk et al. 2021), run with standard
479 parameters. We have used only protein-protein interactions. The produced network possesses
480 1,666 nodes and 10,989 edges, with an average node degree of 13.2 and an average local
481 clustering coefficient of 0.321.

482 The predicted miRNA targeting network was constructed extracting the longest 3'UTR
483 sequence of the top 1000 genes identified in our study, converting the sequences in FASTA
484 format, and parsing the file using the MIRANDA algorithm (Enright et al. 2003) and the mature *C.*
485 *elegans* miRNA list from miRBase release v22.1 (Griffiths-Jones et al. 2006) using stringent
486 parameters (-strict -sc -1.2). MIRANDA produced 1,128 predicted targets for 114 mature *C.*
487 *elegans* miRNAs. Both networks were uploaded to the Network Analyst online software (Xia et al.
488 2015) to produce the network images shown in Main Figure 2B. (Griffiths-Jones et al. 2006).

489

490 **Promoter Analysis**

491 We used custom Perl scripts to extract 2,000 nt from the transcription start site for the top 90
492 genes identified in this study. We then used different custom Perl scripts to calculate the
493 nucleotide distribution. The transcription factor predictions were produced parsing these
494 promoters to the Simple Enrichment Analysis script from the MEME suite software (Bailey et al.
495 2015).

496

497 **Data Availability**

498 Raw reads were submitted to the NCBI Sequence Read Archive
499 (<http://trace.ncbi.nlm.nih.gov/Traces/sra/>) with BioProject ID: PRJNA811605 and
500 Submission ID: SUB11135968. The results of our analyses are available in Excel format
501 as **Supplemental Table S1**.

502

503 **Author Contribution**

504 DJR and MM designed the experiments. QZ performed the experiments described in Main
505 Figure 1, 3-7. HH performed the *lin-31* PAT-Seq immunoprecipitations and prepared the
506 sequencing reactions. MM performed the bioinformatic analysis. MM and DR analyzed the data.
507 MM and DJR led the analysis and interpretation of the data, assembled the Figures, and wrote
508 the manuscript in collaboration with HH. All authors read and approved the final manuscript.

509

510 **Acknowledgments**

511 This work was supported by NIH grant 1R21HD090707 to D.J.R. and 1R01GM118796 to
512 M.M. Some strains were provided by the CGC, which is funded by NIH Office of Research
513 Infrastructure Programs (P40 OD010440). WormBase was used routinely. We thank members of
514 the Reiner lab for discussion and helpful comments on the manuscript.

515

516

517 **FIGURE LEGENDS**

518 **Figure 1: Transgenic scheme to identify the vulval transcriptome. A)** A schematic of VPC
519 fate development. Signal from the anchor cell induces six competent VPCs (P3.p - P8.p) to
520 assume one of three cell fates: 1°, 2° and 3°, with 1° closest to the AC and 2°s flanking the 1°. 1°
521 and 2° cells undergo three rounds of division to generate 22 vulval cells – 8 for the 1° lineage and
522 7 for each of two 2° lineages – which undergo morphogenesis to form the mature vulva in the
523 adult. **B)** We generated transgenes, integrated extrachromosomal arrays *rels27* and *rels28[P_{lin-}*
524 *31::gfp::pab-1::3xFLAG::unc-54 3'UTR]*, to serve as “+PAB-1” bait to identify vulval-specific
525 transcripts. **C)** Tracking DIC (left) and GFP expression (right) from the *rels28* transgene through
526 stages of larval development. (We also observed expression in a handful of unidentified small
527 cells, possibly neurons, in the head and tail; not shown). The control transgene, *rels30*, lacked

528 sequences encoding *pab-1* but still expressed GFP::*3xFLAG* in vulval lineages (not shown). Scale
529 bars = 10 μ m.

530

531 **Figure 2: The vulval transcriptome.** A) A Heatmap comparison of the vulva transcriptome
532 (+PAB-1; median FPKM value of DV3507 and DV3509), as compared to its negative control (-
533 PAB-1; DV3520 negative control). The boxes with yellow or green dotted lines in the heat map
534 indicate genes that were either upregulated or downregulated in the vulva dataset, respectively.
535 Several upregulated genes are shown in the bar chart below the heatmap. B) Summary of the
536 GO term analysis produced by the vulva transcriptome dataset. C) The vulva protein-coding gene
537 interactome (top) and the predicted miRNA targeting network (bottom).

538

539 **Figure 3: Promoter::*GFP* expression patterns of selected genes in the VPC-expressed data**
540 **set. A)** A general schematic of promoter sequences cloned in front of *2xNLS::gfp* and the *unc-54*
541 3'UTR. The solid line represents upstream sequences and dotted line represent inverted *lin-31*
542 coding sequences that contain an enhancer in the pB255 plasmid (Tan et al. 1998). **B)**
543 Epifluorescence images of extrachromosomal transgenic lines generated for this study. Arrows
544 indicate GFP expression in VPCs. i) The *lag-1a* promoter drives expression in VPCs but not in
545 other tissues expected to express LAG-1. ii) The *toe-1* promoter drives expression at high levels
546 in hypodermis and other cell types, including VPCs but not neighboring ventral cord neurons. iii)
547 The *mbi-1a* promoter is expressed in the touch response neurons (TRNs). iv) The *mbi-1b*
548 promoter drives expression in ventral neurons and putative neurons in the head but not VPCs. v)
549 The *shc-1a* drives expression in head neurons and intestinal cells but not VPCs. vi) The promoter
550 of F23A4.7 drives expression in a head neuron but not VPCs.

551

552 **Figure 4: CRISPR tagging strategy for the *lag-1* C-terminus.** **A)** WormBase gene model for
553 *lag-1* (*K08B4.1*) on LGI. By RNAseq analysis in WormBase, the *d* isoform is a small minority. **B)**

554 CRISPR tagging strategy using the SEC approach (Dickinson, et al. 2015). Detection primers are
555 denoted by “QZ” (see **Supplementary Table 4. C**) PCR detection of wild-type and homozygous
556 insertion bands. **D**) Western blot detection using anti-FLAG antibody of endogenous LAG-
557 1::mNeonGreen::3xFLAG protein; the tag portion of the protein is predicted to be 28.8 kD. Isoform
558 D with tag is predicted to be 116.5 kD, while isoforms A, B and C are predicted to be 103.7, 103.5
559 and 98.5 kD, respectively. We detected two general band species but due to gel smiling it was
560 unclear how well they matched predicted sizes. Control anti-tubulin antibody detected the
561 expected 50 kD bands (left two lanes) and the 50 kD marker (right).

562

563 **Figure 5: Expression of tagged endogenous LAG-1::mNeonGreen in VPCs and the ventral**
564 **gonad.** We observed expression and nuclear localization of green fluorescence in the VPCs,
565 vulval lineages and ventral gonad throughout larval development. Notably, we consistently
566 observed decreased but not eliminated nuclear green fluorescence in 1° lineage descendants
567 (P6.px and P6.pxx). Each “x” in lineage notation indicates daughters of an original Pn.p cell. Stage
568 of development is noted on the left. Arrows indicate Pn.p or Pn.px cells at the ventral midline of
569 the animal, later vulval lineages are self-evident. The ventral gonad is not indicated but is directly
570 above the vulval lineages. Scale bars = 10 µm.

571

572 **Figure 6: Dynamic regulation of LAG-1::mNeonGreen expression in embryos.** Expression
573 of LAG-1::mNeonGreen may be absent until the 12-cell stage, and then is expressed at various
574 levels. After, the expression was observed in nuclei of subsets of cells. The stage of development
575 is noted on the left. Scale bars = 10 µm.

576

577 **Figure 7: Other expression of endogenous LAG-1::mNeonGreen. A)** Strong expression was
578 observed in a variety of cells in the head. **B)** Expression was observed in the somatic germline
579 but not in proximal germ cells. We never observed expression in the distal tip cell, but we did

580 observe faint expression in expression in distal-most germ nuclei in the mitotic and transition
581 zones, perhaps reflecting GLP-1/Notch signaling to these nuclei among the germline syncytium.
582 Expression was also observed in sperm. Scale bars = 10 μ m.

583

584

585 **SUPPLEMENTARY DATA**

586 **Supplementary Figure 1:** The *C. elegans* vulval Dataset. A) Sequencing Summary. B) Left: The
587 distribution of the *fpkm* values in experiment (blue) and replicate (orange) samples for each
588 dataset. The plots were generated using the cummeRbund package v. 2.0. Right) Enrichment of
589 VPC-specific genes, indicated by number of genes detected in the experiment, in the replicate
590 and in the overlap of these two datasets in DV3507, DV3509 and DV3520 strains. C) Principal
591 Component Analysis (PCA) shows high correlation among each duplicate within our datasets.

592

593 **Supplementary Figure S2:** Promoter Analysis. A) Sequence analysis of promoter regions for
594 vulva-enriched expressed genes. We extracted and studied the DNA regions 500 bp upstream
595 and 100 bp downstream of the start codon for each of 100 top genes in our dataset compared to
596 a randomly generated datasets of 100 promoters. B) Analysis of enriched motifs in promoters
597 (100 bp from transcription start site) of the top 90 genes detected in our study. This analysis
598 was performed using the MEME Suite software (p-value <.005).

599

600 **Supplementary Table 1:** Ranked list of genes identified in this study.

601

602 **Supplementary Table 2:** Predicted miRNAs and their targets in protein-coding genes
603 expressed in the vulva.

604

605 **Supplementary Table 3:** *C. elegans* strains used in this study.

606

607 **Supplementary Table 4:** Primers used in this study.

608

609 **Supplementary Table 5:** Plasmids used in this study.

610

611

612 REFERENCES

- 613 Andersen EC, Lu X, Horvitz HR. 2006. *C. elegans* ISWI and NURF301 antagonize an Rb-like
614 pathway in the determination of multiple cell fates. *Development* **133**: 2695-2704.
- 615 Arur S, Ohmachi M, Nayak S, Hayes M, Miranda A, Hay A, Golden A, Schedl T. 2009. Multiple
616 ERK substrates execute single biological processes in *Caenorhabditis elegans* germ-line
617 development. *Proc Natl Acad Sci U S A* **106**: 4776-4781.
- 618 Bailey TL, Johnson J, Grant CE, Noble WS. 2015. The MEME Suite. *Nucleic Acids Res* **43**: W39-
619 49.
- 620 Beitel GJ, Tuck S, Greenwald I, Horvitz HR. 1995. The *Caenorhabditis elegans* gene *lin-1* encodes
621 an ETS-domain protein and defines a branch of the vulval induction pathway. *Genes Dev*
622 **9**: 3149-3162.
- 623 Belle I, Zhuang Y. 2014. E proteins in lymphocyte development and lymphoid diseases. *Curr Top*
624 *Dev Biol* **110**: 153-187.
- 625 Blazie SM, Babb C, Wilky H, Rawls A, Park JG, Mangone M. 2015. Comparative RNA-Seq
626 analysis reveals pervasive tissue-specific alternative polyadenylation in *Caenorhabditis*
627 *elegans* intestine and muscles. *BMC Biol* **13**: 4.
- 628 Blazie SM, Geissel HC, Wilky H, Joshi R, Newbern J, Mangone M. 2017. Alternative
629 Polyadenylation Directs Tissue-Specific miRNA Targeting in *Caenorhabditis elegans*
630 Somatic Tissues. *Genetics* **206**: 757-774.
- 631 Braendle C, Felix MA. 2008. Plasticity and errors of a robust developmental system in different
632 environments. *Dev Cell* **15**: 714-724.
- 633 Brenner S. 1974. The genetics of *Caenorhabditis elegans*. *Genetics* **77**: 71-94.
- 634 Christensen S, Kodoyianni V, Bosenberg M, Friedman L, Kimble J. 1996. *lag-1*, a gene required
635 for *lin-12* and *glp-1* signaling in *Caenorhabditis elegans*, is homologous to human CBF1
636 and *Drosophila* Su(H). *Development* **122**: 1373-1383.
- 637 Clandinin TR, Katz WS, Sternberg PW. 1997. *Caenorhabditis elegans* HOM-C genes regulate the
638 response of vulval precursor cells to inductive signal. *Dev Biol* **182**: 150-161.
- 639 Cohen JD, Sparacio AP, Belfi AC, Forman-Rubinsky R, Hall DH, Maul-Newby H, Frand AR,
640 Sundaram MV. 2020. A multi-layered and dynamic apical extracellular matrix shapes the
641 vulva lumen in *Caenorhabditis elegans*. *Elife* **9**.
- 642 Conradt B, Horvitz HR. 1999. The TRA-1A sex determination protein of *C. elegans* regulates
643 sexually dimorphic cell deaths by repressing the *egl-1* cell death activator gene. *Cell* **98**:
644 317-327.

- 645 Costa M, Raich W, Agbunag C, Leung B, Hardin J, Priess JR. 1998. A putative catenin-cadherin
646 system mediates morphogenesis of the *Caenorhabditis elegans* embryo. *J Cell Biol* **141**:
647 297-308.
- 648 de la Cova C, Townley R, Regot S, Greenwald I. 2017. A Real-Time Biosensor for ERK Activity
649 Reveals Signaling Dynamics during *C. elegans* Cell Fate Specification. *Dev Cell* **42**: 542-
650 553 e544.
- 651 Dickinson DJ, Pani AM, Heppert JK, Higgins CD, Goldstein B. 2015. Streamlined Genome
652 Engineering with a Self-Excising Drug Selection Cassette. *Genetics* **200**: 1035-1049.
- 653 Duong T, Rasmussen NR, Ballato E, Mote FS, Reiner DJ. 2020. The Rheb-TORC1 signaling axis
654 functions as a developmental checkpoint. *Development* **147**.
- 655 Ecsedi M, Rausch M, Grosshans H. 2015. The let-7 microRNA directs vulval development through
656 a single target. *Dev Cell* **32**: 335-344.
- 657 Eisenmann DM. 2005. Wnt signaling. *WormBook* doi:10.1895/wormbook.1.7.1: 1-17.
- 658 Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. 2003. MicroRNA targets in
659 *Drosophila*. *Genome Biol* **5**: R1.
- 660 Ferguson EL, Sternberg PW, Horvitz HR. 1987. A genetic pathway for the specification of the
661 vulval cell lineages of *Caenorhabditis elegans*. *Nature* **326**: 259-267.
- 662 Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J. 2000.
663 Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference.
664 *Nature* **408**: 325-330.
- 665 Galvin BD, Kim S, Horvitz HR. 2008. *Caenorhabditis elegans* genes required for the engulfment
666 of apoptotic corpses function in the cytotoxic cell deaths induced by mutations in *lin-24*
667 and *lin-33*. *Genetics* **179**: 403-417.
- 668 Gleason JE, Szyleyko EA, Eisenmann DM. 2006. Multiple redundant Wnt signaling components
669 function in two processes during *C. elegans* vulval development. *Dev Biol* **298**: 442-457.
- 670 Grants JM, Ying LT, Yoda A, You CC, Okano H, Sawa H, Taubert S. 2016. The Mediator Kinase
671 Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell
672 Fate Specification in *Caenorhabditis elegans*. *Genetics* **202**: 583-599.
- 673 Green JL, Inoue T, Sternberg PW. 2007. The *C. elegans* ROR receptor tyrosine kinase, CAM-1,
674 non-autonomously inhibits the Wnt pathway. *Development* **134**: 4053-4062.
- 675 Green JL, Inoue T, Sternberg PW. 2008. Opposing Wnt pathways orient cell polarity during
676 organogenesis. *Cell* **134**: 646-656.
- 677 Greenwald I. 2005. LIN-12/Notch signaling in *C. elegans*. *WormBook*
678 doi:10.1895/wormbook.1.10.1: 1-16.
- 679 Greenwald I, Kovall R. 2013. Notch signaling: genetics and structure. *WormBook*
680 doi:10.1895/wormbook.1.10.2: 1-28.
- 681 Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. miRBase: microRNA
682 sequences, targets and gene nomenclature. *Nucleic Acids Res* **34**: D140-144.
- 683 Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ. 2005. The temporal patterning
684 microRNA let-7 regulates several transcription factors at the larval to adult transition in *C.*
685 *elegans*. *Dev Cell* **8**: 321-330.
- 686 Hagedorn EJ, Sherwood DR. 2011. Cell invasion through basement membrane: the anchor cell
687 breaches the barrier. *Curr Opin Cell Biol* **23**: 589-596.
- 688 Hart AH, Reventar R, Bernstein A. 2000. Genetic analysis of ETS genes in *C. elegans*. *Oncogene*
689 **19**: 6400-6408.

- 690 Hoier EF, Mohler WA, Kim SK, Hajnal A. 2000. The *Caenorhabditis elegans* APC-related gene
691 *apr-1* is required for epithelial cell migration and Hox gene expression. *Genes Dev* **14**: 874-
692 886.
- 693 Horvitz HR, Brenner S, Hodgkin J, Herman RK. 1979. A uniform genetic nomenclature for the
694 nematode *Caenorhabditis elegans*. *Mol Gen Genet* **175**: 129-133.
- 695 Hrach HC, O'Brien S, Steber HS, Newbern J, Rawls A, Mangone M. 2020. Transcriptome changes
696 during the initiation and progression of Duchenne muscular dystrophy in *Caenorhabditis*
697 *elegans*. *Hum Mol Genet* **29**: 1607-1623.
- 698 Hwang HY, Olson SK, Brown JR, Esko JD, Horvitz HR. 2003. The *Caenorhabditis elegans* genes
699 *sqv-2* and *sqv-6*, which are required for vulval morphogenesis, encode glycosaminoglycan
700 galactosyltransferase II and xylosyltransferase. *J Biol Chem* **278**: 11735-11738.
- 701 Inoue T, Oz HS, Wiland D, Gharib S, Deshpande R, Hill RJ, Katz WS, Sternberg PW. 2004. *C.*
702 *elegans* LIN-18 is a Ryk ortholog and functions in parallel to LIN-17/Frizzled in Wnt
703 signaling. *Cell* **118**: 795-806.
- 704 Inoue T, Sherwood DR, Aspöck G, Butler JA, Gupta BP, Kirouac M, Wang M, Lee PY, Kramer
705 JM, Hope I et al. 2002. Gene expression markers for *Caenorhabditis elegans* vulval cells.
706 *Gene Expr Patterns* **2**: 235-241.
- 707 Inoue T, Wang M, Ririe TO, Fernandes JS, Sternberg PW. 2005. Transcriptional network
708 underlying *Caenorhabditis elegans* vulval development. *Proc Natl Acad Sci U S A* **102**:
709 4972-4977.
- 710 Kidd AR, 3rd, Muniz-Medina V, Der CJ, Cox AD, Reiner DJ. 2015. The *C. elegans* Chp/Wrch
711 Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell
712 Polarity. *PLoS One* **10**: e0133226.
- 713 Kimble J, Crittenden SL. 2005. Germline proliferation and its control. *WormBook*
714 doi:10.1895/wormbook.1.13.1: 1-14.
- 715 Kirouac M, Sternberg PW. 2003. cis-Regulatory control of three cell fate-specific genes in vulval
716 organogenesis of *Caenorhabditis elegans* and *C. briggsae*. *Dev Biol* **257**: 85-103.
- 717 Kishore RS, Sundaram MV. 2002. *ced-10* Rac and *mig-2* function redundantly and act with *unc-*
718 *73* trio to control the orientation of vulval cell divisions and migrations in *Caenorhabditis*
719 *elegans*. *Dev Biol* **241**: 339-348.
- 720 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**: 357-
721 359.
- 722 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R,
723 Genome Project Data Processing S. 2009. The Sequence Alignment/Map format and
724 SAMtools. *Bioinformatics* **25**: 2078-2079.
- 725 Luo KL, Underwood RS, Greenwald I. 2020. Positive autoregulation of *lag-1* in response to LIN-
726 *12* activation in cell fate decisions during *C. elegans* reproductive system development.
727 *Development* **147**.
- 728 Martinez NJ, Ow MC, Reece-Hoyes JS, Barrasa MI, Ambros VR, Walhout AJ. 2008. Genome-
729 scale spatiotemporal analysis of *Caenorhabditis elegans* microRNA promoter activity.
730 *Genome Res* **18**: 2005-2015.
- 731 Miller LM, Gallegos ME, Morisseau BA, Kim SK. 1993. *lin-31*, a *Caenorhabditis elegans* HNF-
732 *3/fork* head transcription factor homolog, specifies three alternative cell fates in vulval
733 development. *Genes Dev* **7**: 933-947.

- 734 Miller LM, Hess HA, Doroquez DB, Andrews NM. 2000. Null mutations in the *lin-31* gene
735 indicate two functions during *Caenorhabditis elegans* vulval development. *Genetics* **156**:
736 1595-1602.
- 737 Miller LM, Waring DA, Kim SK. 1996. Mosaic analysis using a *ncl-1* (+) extrachromosomal array
738 reveals that *lin-31* acts in the Pn.p cells during *Caenorhabditis elegans* vulval development.
739 *Genetics* **143**: 1181-1191.
- 740 Myers TR, Greenwald I. 2007. Wnt signal from multiple tissues and *lin-3*/EGF signal from the
741 gonad maintain vulval precursor cell competence in *Caenorhabditis elegans*. *Proc Natl*
742 *Acad Sci U S A* **104**: 20368-20373.
- 743 Nakdimon I, Walser M, Frohli E, Hajnal A. 2012. PTEN negatively regulates MAPK signaling
744 during *Caenorhabditis elegans* vulval development. *PLoS Genet* **8**: e1002881.
- 745 Oka T, Toyomura T, Honjo K, Wada Y, Futai M. 2001. Four subunit a isoforms of *Caenorhabditis*
746 *elegans* vacuolar H⁺-ATPase. Cell-specific expression during development. *J Biol Chem*
747 **276**: 33079-33085.
- 748 Parry DH, Xu J, Ruvkun G. 2007. A whole-genome RNAi Screen for *C. elegans* miRNA pathway
749 genes. *Curr Biol* **17**: 2013-2022.
- 750 Poulin G, Dong Y, Fraser AG, Hopper NA, Ahringer J. 2005. Chromatin regulation and
751 sumoylation in the inhibition of Ras-induced vulval development in *Caenorhabditis*
752 *elegans*. *EMBO J* **24**: 2613-2623.
- 753 Priess JR. 2005. Notch signaling in the *C. elegans* embryo. *WormBook*
754 doi:10.1895/wormbook.1.4.1: 1-16.
- 755 Pujol N, Bonnerot C, Ewbank JJ, Kohara Y, Thierry-Mieg D. 2001. The *Caenorhabditis elegans*
756 *unc-32* gene encodes alternative forms of a vacuolar ATPase a subunit. *J Biol Chem* **276**:
757 11913-11921.
- 758 Rasmussen NR, Dickinson DJ, Reiner DJ. 2018. Ras-Dependent Cell Fate Decisions Are
759 Reinforced by the RAP-1 Small GTPase in *Caenorhabditis elegans*. *Genetics* **210**: 1339-
760 1354.
- 761 Rasmussen NR, Reiner DJ. 2021. Nuclear translocation of the tagged endogenous MAPK MPK-1
762 denotes a subset of activation events in *C. elegans* development. *J Cell Sci* **134**.
- 763 Ririe TO, Fernandes JS, Sternberg PW. 2008. The *Caenorhabditis elegans* vulva: a post-embryonic
764 gene regulatory network controlling organogenesis. *Proc Natl Acad Sci U S A* **105**: 20095-
765 20099.
- 766 Schlager B, Roseler W, Zheng M, Gutierrez A, Sommer RJ. 2006. HAIRY-like transcription
767 factors and the evolution of the nematode vulva equivalence group. *Curr Biol* **16**: 1386-
768 1394.
- 769 Shemer G, Podbilewicz B. 2002. LIN-39/Hox triggers cell division and represses EFF-1/fusogen-
770 dependent vulval cell fusion. *Genes Dev* **16**: 3136-3141.
- 771 Shephard F, Adenle AA, Jacobson LA, Szewczyk NJ. 2011. Identification and functional
772 clustering of genes regulating muscle protein degradation from amongst the known *C.*
773 *elegans* muscle mutants. *PLoS One* **6**: e24686.
- 774 Shin H, Braendle C, Monahan KB, Kaplan REW, Zand TP, Mote FS, Peters EC, Reiner DJ. 2019.
775 Developmental fidelity is imposed by genetically separable RalGEF activities that mediate
776 opposing signals. *PLoS Genet* **15**: e1008056.
- 777 Shin H, Kaplan REW, Duong T, Fakieh R, Reiner DJ. 2018. Ral Signals through a MAP4 Kinase-
778 p38 MAP Kinase Cascade in *C. elegans* Cell Fate Patterning. *Cell Rep* **24**: 2669-2681
779 e2665.

- 780 Shin H, Reiner DJ. 2018. The Signaling Network Controlling *C. elegans* Vulval Cell Fate
781 Patterning. *J Dev Biol* **6**.
- 782 Speese S, Petrie M, Schuske K, Ailion M, Ann K, Iwasaki K, Jorgensen EM, Martin TF. 2007.
783 UNC-31 (CAPS) is required for dense-core vesicle but not synaptic vesicle exocytosis in
784 *Caenorhabditis elegans*. *J Neurosci* **27**: 6150-6162.
- 785 Spiri S, Berger S, Mereu L, DeMello A, Hajnal A. 2022. Reciprocal EGFR signaling in the anchor
786 cell ensures precise inter-organ connection during *Caenorhabditis elegans* vulval
787 morphogenesis. *Development* **149**.
- 788 Sternberg PW. 2005. Vulval development. *WormBook* doi:10.1895/wormbook.1.6.1: 1-28.
- 789 Sternberg PW. June 25, 2005. Vulval development. In *WormBook*, doi:1551-8507 (ed. TCeR
790 Community). WormBook.
- 791 Steven R, Kubiseski TJ, Zheng H, Kulkarni S, Mancillas J, Ruiz Morales A, Hogue CW, Pawson
792 T, Culotti J. 1998. UNC-73 activates the Rac GTPase and is required for cell and growth
793 cone migrations in *C. elegans*. *Cell* **92**: 785-795.
- 794 Sulston JE, Horvitz HR. 1977. Post-embryonic cell lineages of the nematode, *Caenorhabditis*
795 *elegans*. *Dev Biol* **56**: 110-156.
- 796 Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M,
797 Fang T, Bork P et al. 2021. The STRING database in 2021: customizable protein-protein
798 networks, and functional characterization of user-uploaded gene/measurement sets.
799 *Nucleic Acids Res* **49**: D605-D612.
- 800 Takacs-Vellai K, Vellai T, Chen EB, Zhang Y, Guerry F, Stern MJ, Muller F. 2007.
801 Transcriptional control of Notch signaling by a HOX and a PBX/EXD protein during
802 vulval development in *C. elegans*. *Dev Biol* **302**: 661-669.
- 803 Tan PB, Lackner MR, Kim SK. 1998. MAP kinase signaling specificity mediated by the LIN-1
804 Ets/LIN-31 WH transcription factor complex during *C. elegans* vulval induction. *Cell* **93**:
805 569-580.
- 806 Tennessen JM, Gardner HF, Volk ML, Rougvie AE. 2006. Novel heterochronic functions of the
807 *Caenorhabditis elegans* period-related protein LIN-42. *Dev Biol* **289**: 30-43.
- 808 Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ,
809 Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated
810 transcripts and isoform switching during cell differentiation. *Nat Biotechnol* **28**: 511-515.
- 811 Underwood RS, Deng Y, Greenwald I. 2017. Integration of EGFR and LIN-12/Notch Signaling
812 by LIN-1/Elk1, the Cdk8 Kinase Module, and SUR-2/Med23 in Vulval Precursor Cell Fate
813 Patterning in *Caenorhabditis elegans*. *Genetics* **207**: 1473-1488.
- 814 Wagmaister JA, Gleason JE, Eisenmann DM. 2006a. Transcriptional upregulation of the *C.*
815 *elegans* Hox gene *lin-39* during vulval cell fate specification. *Mech Dev* **123**: 135-150.
- 816 Wagmaister JA, Miley GR, Morris CA, Gleason JE, Miller LM, Kornfeld K, Eisenmann DM.
817 2006b. Identification of cis-regulatory elements from the *C. elegans* Hox gene *lin-39*
818 required for embryonic expression and for regulation by the transcription factors LIN-1,
819 LIN-31 and LIN-39. *Dev Biol* **297**: 550-565.
- 820 Wang W, Lufkin T. 2005. Hmx homeobox gene function in inner ear and nervous system cell-type
821 specification and development. *Experimental cell research* **306**: 373-379.
- 822 Xia J, Gill EE, Hancock RE. 2015. NetworkAnalyst for statistical, visual and network-based meta-
823 analysis of gene expression data. *Nat Protoc* **10**: 823-844.
- 824 Yang L, Sym M, Kenyon C. 2005. The roles of two *C. elegans* HOX co-factor orthologs in cell
825 migration and vulva development. *Development* **132**: 1413-1428.

- 826 Yemini E, Lin A, Nejatbakhsh A, Varol E, Sun R, Mena GE, Samuel ADT, Paninski L,
827 Venkatachalam V, Hobert O. 2021. NeuroPAL: A Multicolor Atlas for Whole-Brain
828 Neuronal Identification in *C. elegans*. *Cell* **184**: 272-288 e211.
- 829 Yoo AS, Bais C, Greenwald I. 2004. Crosstalk between the EGFR and LIN-12/Notch pathways in
830 *C. elegans* vulval development. *Science* **303**: 663-666.
- 831 Yoo AS, Greenwald I. 2005. LIN-12/Notch activation leads to microRNA-mediated down-
832 regulation of Vav in *C. elegans*. *Science* **310**: 1330-1333.
- 833

834 **Supplementary Table 3 - Strains**

Strain	Genotype	Used in figure
DV3485	<i>reEx204</i> [<i>P_{lin-31}::gfp::pab-1::3xFLAG::+P_{myo-2}::mCherry</i>]	N.A.
DV3502	<i>reEx207</i> [<i>P_{lin-31}::gfp::3xFLAG+P_{myo-2}::mCherry</i>]	N.A.
DV3507	<i>rels27</i> [<i>P_{lin-31}::gfp::pab-1::3xFLAG+P_{myo-2}::mCherry</i>]	Fig. 2
DV3509	<i>rels28</i> [<i>P_{lin-31}::gfp::pab-1::3xFLAG+P_{myo-2}::mCherry</i>] IV	Fig. 1C, Fig. 2
DV3520	<i>rels30</i> [<i>P_{lin-31}::gfp::3xFLAG+P_{myo-2}::mCherry</i>]	Fig. 2
DV3761	<i>reEx286</i> [<i>P_{toe-1}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3D
DV3741	<i>reEx280</i> [<i>P_{F23A7.4}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3H
DV3725	<i>reEx270</i> [<i>P_{lag-1a}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3C
DV3723	<i>reEx268</i> [<i>P_{mnk-1}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3B
DV3758	<i>reEx283</i> [<i>P_{mbl-1(short)}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3E
DV3757	<i>reEx282</i> [<i>P_{mbl-1(long)}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3F
DV3759	<i>reEx284</i> [<i>P_{shc-1a}::2xNLS::gfp+P_{myo-2}::mCherry</i>]	Fig. 3G
DV3790	<i>lag-1</i> (<i>re310</i> [<i>lag-1::mNeonGreen::3xFLAG</i>]) IV	Figs. 4-7

835

Supplementary Table 4 - Primers

Name	Primer 5'>3'	Use for
QZ17f	TAGAACATTTTCAGGAGGACCCTTGGCTAGCGATGAG TAAAGGAGAAGAACTTTTCACTG	<i>gfp::pab-1::3xFLAG</i> fragment subcloning into pFSM11 vector to generate pQZ2
QZ23r	GATGGCGATCTGATGACAGCGGCCGATGCCGAGCTG GCCTACTTGTCTCGTCGTCGTCCTTG	
QZ35f	GCCAGCTCCGCATCGGCCGCTGTCATC	
QZ36r	CGCTAGCCAAGGGTCCTCCTGAAAATGTTCTATGTTA TGTTAGTATCATTGAAACATAC	
QZ37r	GAGCTCTTTGTATAGTTCATCCATGCCATG	<i>pab-1</i> deletion in pQZ2
QZ38f	GACTACAAGGACCACGACGGCGA	
QZ165f	AATACGACTCACTATAGGGCGAATTGGGTACGCCGC GGGATGGTTGGTTTGTGAGTGAG	<i>F23A7.4</i> promoter fragment subcloning into pPD95.67
QZ166r	TCGAAACATACCTTTGGGTCCTTTGGCCAATCCATGA CTTAATTGGAATTTACATAACCG	
QZ163f	CTATAGGGCGAATTGGGTACGCCGCGGGGCATTTTT ATTTTTGTCACAAAATATGTCAAC	<i>lag-1</i> promoter fragment subcloning into pPD95.67
QZ164r	GAAACATACCTTTGGGTCCTTTGGCCAATCCATTTCC TGAAATTTCTGAATGTTATTTTC	
QZ167f	ACTATAGGGCGAATTGGGTACGCCGCGGGTAGACAA AAAAGTTAGATTCATATGGACATG	<i>mnk-1</i> promoter fragment subcloning into pPD95.67
QZ168r	TCGAAACATACCTTTGGGTCCTTTGGCCAATCCATATT GTGTTGAATGAATGGTAGAATG	
QZ182f	CTCACTATAGGGCGAATTGGGTACGCCGCGGGCGTC AGATTACGCACATTCTACGCAATC	<i>toe-1</i> promoter fragment subcloning into pPD95.67
QZ175r	CATTCGAAACATACCTTTGGGTCCTTTGGCCAATCTG TCAACGACGTCGCCATtcttatg	
QZ178f	AATACGACTCACTATAGGGCGAATTGGGTACGCCGC GGGCATTAGGCGCTAAACTAAAAG	<i>mb1-1</i> promoter fragment subcloning into pPD95.67
QZ179r	TAGTATCATTGAAACATACCTTTGGGTCCTTTGGCC AATCaatAAGGTGTGAGGAGGTG	
QZ180f	CGTAATACGACTCACTATAGGGCGAATTGGGTACGCC GCGGGcacatttgcgtcgggac	<i>mb1-1</i> promoter fragment subcloning into pPD95.67
QZ181r	TTAGTATCATTGAAACATACCTTTGGGTCCTTTGGCC AATCCGTTCCAGCGGCATTACT	
QZ184Uparm forward	gacgttgtaaaacgacgcccagtcgccggcaGGATGTTTACGAAT AGGACAACCGGCGAT	Homology arms (670 bp of <i>lag-1</i> gene) subcloned into pDD268
QZ185Uparm reverse	CATCGATGCTCCTGAGGCTCCCGATGCTCCGTAATTG GACACAATTCTGCACGGTCCATG	
QZ186Downarm forward	CGTGATTACAAGGATGACGATGACAAGAGATAGattcca ctAtcgcgggattactgtatc	homology arm (674 bp of <i>lag-1</i> 3'UTR) subcloned into pDD268
QZ187Downarm reverse	ggaaacagctatgacctgttatcgatttcgtcaaatgtacaccgacgagaatc tgaaG	
QZ188f	cccgcgagagGTTTAAGAGCTATGCTGG	


QZ18r	attactgtatAAGACATCTCGCAATAGG	Mutagenesis PCR primer for <i>lag-1</i> CRISPR sgRNA-cas9 plasmid
QZ197f	GTTGTCGGTTCACCTTGAAGTT	<i>lag-1</i> ::mNG(re310) genotyping
QZ198r	CTTGGTGGACTTGAGGTTGAG	
QZ199r	GGAATAGACCCAGCTTTCTTGTAC	

Supplementary Table # - Plasmids


Name	Description	Used for
P221 pap	<i>gfp::pab-1::3xFLAG</i>	Constructing <i>pab-1</i> bait
pB25 5	<i>P_{lin-31}::unc-54 3'UTR</i>	Constructing <i>pab-1</i> bait
pQZ2	<i>P_{lin-31}::gfp::pab-1::3xFLAG::unc-54 3'UTR</i>	Generating bait array: DV3507 and DV3509
pQZ3	<i>P_{lin-31}::gfp::3xFLAG::unc-54 3'UTR</i>	Generating control array: DV3520
ppD9 5.67	<i>2xFLAG::gfp::unc-54 3'UTR</i>	backbone for promoter reporter construction
pCFJ 90	<i>P_{myo-2}::mCherry::unc-54 3'utr</i>	Co-injection marker
ppD1 18.33	<i>P_{myo-2}::gfp::unc-54 3'utr</i>	Co-injection marker
pF23 A7.4	<i>P_{F23A7.4} (KanR)</i>	commercial promoterome clone
pR16 6.2a	<i>P_{mnk-1} (KanR)</i>	commercial promoterome clone
pK08 B4.1a	<i>P_{lag-1} (KanR)</i>	commercial promoterome clone
pQZ3 0	<i>P_{lag-1}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3725
pQZ3 1	<i>P_{F23A7.4}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3741
pQZ3 2	<i>P_{mnk-1}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3723
pQZ3 3	<i>P_{mbl-1(short)}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3758
pQZ3 4	<i>P_{mbl-1(long)}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3757
pQZ3 5	<i>P_{toe-1}::2xNLS::gfp::unc-54 3'UTR</i>	transgenic strain DV3761
pQZ3 6	Homology arms (670 bp of <i>lag-1</i> final exon and 674 bp of <i>lag-1</i> 3'UTR) subcloned into pDD268	LAG-1::mNG ^{3xFLAG} CRISPR knock-in (repair template)
pQZ3 7	Mutagenized pJW1236 using primers, QZ188 and QZ189	LAG-1::mNG ^{3xFLAG} CRISPR knock-in (sgRNA-Cas9 plasmid)

1
2


A







B



C






ID	Source	Term ID	Term Name	Padj (query_1)
1	GO:CC	GO:0005622	intracellular anatomical structure	9.862×10 ⁻³³
2	KEGG	KEGG:04010	MAPK signaling pathway	2.048×10 ⁻⁹
3	GO:BP	GO:0032502	developmental process	1.461×10 ⁻⁹
4	GO:MF	GO:0005198	structural molecule activity	6.811×10 ⁻¹⁴
5	GO:MF	GO:0005515	protein binding	1.607×10 ⁻¹⁴
6	GO:BP	GO:0007275	multicellular organism development	3.194×10 ⁻⁸
7	GO:BP	GO:0016070	RNA metabolic process	2.969×10 ⁻⁷
8	GO:BP	GO:0048856	anatomical structure development	8.225×10 ⁻⁸
9	GO:BP	GO:0051094	positive regulation of developmental process	1.859×10 ⁻⁸


A




B




A




B





C




D







A



B

